Dare Bioscience (NASDAQ:DARE) Stock Picked Up by Analysts at LADENBURG THALM/SH SH

Investment analysts at LADENBURG THALM/SH SH started coverage on shares of Dare Bioscience (NASDAQ:DARE) in a report released on Monday, Briefing.com reports. The firm set a “buy” rating and a $2.00 price target on the biotechnology company’s stock. LADENBURG THALM/SH SH‘s price target points to a potential upside of 209.65% from the company’s previous close.

Several other equities research analysts have also recently commented on DARE. Benchmark reaffirmed a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. HC Wainwright reissued a “buy” rating on shares of Dare Bioscience in a research report on Monday, August 17th. UBS Group set a $1.00 price target on shares of Dare Bioscience in a report on Monday, September 14th. Finally, Weiss Ratings cut shares of Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Dare Bioscience Price Performance

Shares of DARE stock opened at $0.65 on Monday. Dare Bioscience has a twelve month low of $0.62 and a twelve month high of $3.78. The business’s fifty day moving average is $0.76 and its 200 day moving average is $1.57. The stock has a market cap of $12.70 million, a price-to-earnings ratio of -0.92 and a beta of 1.01.

Dare Bioscience (NASDAQ:DARE) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.10. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.00 million. Dare Bioscience had a negative return on equity of 748.30% and a negative net margin of 803.80%. Equities research analysts expect that Dare Bioscience will post -0.69 earnings per share for the current fiscal year.

About Dare Bioscience

Daré Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies designed to address women’s health needs. Its research programs span contraception, vaginal and reproductive health, fertility, pregnancy and postpartum care, and menopause.

The company’s lead commercial product, XACIATO (clindamycin phosphate) vaginal gel 2%, is an FDA-approved prescription treatment for bacterial vaginosis. Daré’s development pipeline has also included Ovaprene, a hormone-free monthly intravaginal contraceptive, and investigational candidates intended to address contraception, sexual health, vaginal conditions and hormone-related disorders.

Daré Bioscience is headquartered in San Diego, California, and conducts development activities through collaborations with biotechnology, pharmaceutical and academic partners.